CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Index movements reflect changes in component stock prices, earnings, macro data, and capital flows. This overview highlights the main drivers behind daily swings.
18,176 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
When Rezolve AI announced a stock buyback and reaffirmed guidance, rezolve stock soared higher, signaling renewed inv...
As the energy transition unfolds, two giants stand out: Chevron and Exxon Mobil. This guide breaks down which stock m...
Apple extends Broadcom’s supply agreement through 2031, anchoring cash flow and accelerating AI chip growth. Here’s w...
SpaceX held firm through a choppy month, outperforming peers in the space stock group. The market’s rotation favored ...
As Tesla prepares for its July 22 report, investors are focused on margin expansion, software and services momentum, ...
Two AI-focused names have pulled back recently, but their paths diverge. This guide breaks down why palantir sandisk ...
As Deere (DE) releases its 2026 earnings outlook, investors weigh crop cycles, equipment demand, and margin trends. T...
PayPal sits near $42 after a tough year, sparking a lively debate on whether the stock is a bargain or a trap as Q4 r...
Applied Optoelectronics is poised to report Q4 FY2025 results after the close on Feb. 26, 2026. Analysts expect reven...
Thor Industries reports a dramatic EPS surprise for Q2, with revenue rising modestly. Yet cash flow weakness and unev...
Oracle defies the mood of a bruised AI rally, with Jefferies sticking to a buy and highlighting accelerating cloud gr...